Neoadjuvant Therapy Prior to Prostatectomy - Mary-Ellen Taplin

January 30, 2019

In this conversation, Mary-Ellen Taplin reviews her work from the past nine years in the area of neoadjuvanct therapies prior to prostatectomy.  Mary-Ellen discusses how research on combining systematic therapy with prostatectomy when next generation androgen-AR axis inhibitors were developed have now lead to the launch of a large, international phase 3 trial.


Mary-Ellen Taplin, MD Chair, Executive Committee for Clinical Research Director of Clinical Research, Lank Center for Genitourinary Oncology Institute Physician, Dana-Farber Cancer Institute Professor of Medicine, Harvard Medical School

Alicia Morgans, MD, MPH, Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.